RxDoctor Payments Data

James Yanes, MD

Internal Medicine · Tucson, AZNPI 1730372251

Payments from drug & device makers

$709in general payments, 2019–2025

Across 28 payments — averaging $25.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$190
  • Abbott$141
  • AbbVie$59
  • Dexcom, Inc.$56
  • Amgen$52
  • GSK$37
  • plus $175 from 7 others

What the payments were for

  • Food & beverage$709100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$709 in reported general payments places this provider in the 70th percentile of 2,212 internal medicine providers in Arizona.

See all internal medicine providers in Arizona

Medicare billing

Part B allowed, 2024
$156,884
Medicare patients
361
Services billed
5,062

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide39$60,344
EliquisApixaban48$56,614
JardianceEmpagliflozin28$46,239
XareltoRivaroxaban17$26,626
JanuviaSitagliptin Phosphate17$26,488
TrulicityDulaglutide18$24,872
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$7,117
Lantus SolostarInsulin Glargine,hum.Rec.Anlog22$2,792
Rosuvastatin Calcium176$2,067
Levothyroxine Sodium165$1,692
Azelastine Hcl47$1,687
Atorvastatin Calcium216$1,529
Omeprazole88$1,518
Lisinopril185$1,496
Duloxetine Hcl44$1,358

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$30$60,34439 claims
PfizerEliquis$33$56,61448 claims
MerckJanuvia$31$26,48817 claims
Lilly USA, LLCTrulicity$190$24,87218 claims
GSKTrelegy Ellipta$37$7,11711 claims
AbbVieSynthroid$59$55624 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,212 internal medicine providers in Arizona.

Other internal medicine in Tucson

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →